This study is investigating if adding the drugs gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy (methotrexate, doxorubicin, cisplatin) is a more effective and safe treatment for people with osteosarcoma (a type of bone cancer) that has spread (metastasis). Researchers will also learn how osteosarcoma survives chemotherapy by studying tumor samples. The study aims to enroll 45 participants between 6 and 49 years old who have newly diagnosed, metastatic osteosarcoma. Success will be measured by how long participants live without their cancer getting worse (progression-free survival) at 12 months, and how long they live overall (overall survival) at 24 months. The current status of this study is unclear.

Study design

This study is an interventional study with a planned enrollment of 45 participants. It is not specified if it is randomized or blinded.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed to measure progression-free survival at 12 months and overall survival at 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.